Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011 (2011), Article ID 307875, 9 pages
http://dx.doi.org/10.4061/2011/307875
Review Article

Therapeutic Effects of Hydrogen in Animal Models of Parkinson's Disease

1Laboratory of Pathophysiology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan
2Division of Neurofunctional Genomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan

Received 15 September 2010; Revised 5 January 2011; Accepted 14 March 2011

Academic Editor: David S. Park

Copyright © 2011 Kyota Fujita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage, “Mechanisms Underlying Inflammation in Neurodegeneration,” Cell, vol. 140, no. 6, pp. 918–934, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. E. Lang and A. M. Lozano, “Parkinson's disease,” The New England Journal of Medicine, vol. 339, no. 15, pp. 1044–1053, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ziering, L. Berger, S. D. Heineman, and J. Lee, “Piperidine derivatives. Part III. 4-arylpiperidines,” Journal of Organic Chemistry, vol. 12, no. 6, pp. 894–903, 1947. View at Google Scholar · View at Scopus
  5. S. Przedborski, K. Tieu, C. Perier, and M. Vila, “MPTP as a mitochondrial neurotoxic model of Parkinson's disease,” Journal of Bioenergetics and Biomembranes, vol. 36, no. 4, pp. 375–379, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. F. Blandini, M. T. Armentero, and E. Martignoni, “The 6-hydroxydopamine model: news from the past,” Parkinsonism and Related Disorders, vol. 14, no. 2, pp. S124–S129, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. W. Langston, I. Irwin, E. B. Langston, and L. S. Forno, “1-Methyl-4-phenylpyridinium ion (MPP): identification of a metabolite of MPTP, a toxin selective to the substantia nigra,” Neuroscience Letters, vol. 48, no. 1, pp. 87–92, 1984. View at Google Scholar · View at Scopus
  8. K. Chiba, A. Trevor, and N. Castagnoli, “Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase,” Biochemical and Biophysical Research Communications, vol. 120, no. 2, pp. 574–578, 1984. View at Google Scholar · View at Scopus
  9. K. Chiba, L. A. Peterson, and K. P. Castagnoli, “Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Drug Metabolism and Disposition, vol. 13, no. 3, pp. 342–347, 1985. View at Google Scholar · View at Scopus
  10. L. A. Peterson, P. S. Caldera, A. Trevor, K. Chiba, and N. Castagnoli, “Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium Species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Journal of Medicinal Chemistry, vol. 28, no. 10, pp. 1432–1436, 1985. View at Google Scholar · View at Scopus
  11. J. A. Javitch, R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder, “Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 7, pp. 2173–2177, 1985. View at Google Scholar · View at Scopus
  12. R. R. Ramsay, J. Dadgar, A. Trevor, and T. P. Singer, “Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP,” Life Sciences, vol. 39, no. 7, pp. 581–588, 1986. View at Google Scholar · View at Scopus
  13. R. R. Ramsay and T. P. Singer, “Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria,” The Journal of Biological Chemistry, vol. 261, no. 17, pp. 7585–7587, 1986. View at Google Scholar · View at Scopus
  14. W. J. Nicklas, I. Vyas, and R. E. Heikkila, “Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine,” Life Sciences, vol. 36, no. 26, pp. 2503–2508, 1985. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Mizuno, N. Sone, and T. Saitoh, “Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain,” Journal of Neurochemistry, vol. 48, no. 6, pp. 1787–1793, 1987. View at Google Scholar · View at Scopus
  16. P. Chan, L. E. DeLanney, I. Irwin, J. W. Langston, and D. Di Monte, “Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain,” Journal of Neurochemistry, vol. 57, no. 1, pp. 348–351, 1991. View at Google Scholar · View at Scopus
  17. G. P. Davey, S. Peuchen, and J. B. Clark, “Energy thresholds in brain mitochondria: potential involvement in neurodegeneration,” The Journal of Biological Chemistry, vol. 273, no. 21, pp. 12753–12757, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Jackson-Lewis and S. Przedborski, “Protocol for the MPTP mouse model of Parkinson's disease,” Nature Protocols, vol. 2, no. 1, pp. 141–151, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. K. Fujita, T. Seike, N. Yutsudo et al., “Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease,” PLoS ONE, vol. 4, no. 9, Article ID e7247, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. E. J. Benner, R. Banerjee, A. D. Reynolds et al., “Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons,” PLoS ONE, vol. 3, no. 1, Article ID e1376, 2008. View at Publisher · View at Google Scholar · View at PubMed
  21. F. Fornai, O. M. Schlüter, P. Lenzi et al., “Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3413–3418, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. D. D. Song and S. N. Haber, “Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting,” Journal of Neuroscience, vol. 20, no. 13, pp. 5102–5114, 2000. View at Google Scholar
  23. X. Du, N. D. Stull, and L. Iacovitti, “Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons,” Brain Research, vol. 680, no. 1-2, pp. 229–233, 1995. View at Publisher · View at Google Scholar
  24. J. T. Greenamyre, “Dopaminergic neurons intrinsic to the primate striatum,” Journal of Neuroscience, vol. 17, no. 17, pp. 6761–6768, 1997. View at Google Scholar
  25. G. E. Meredith, “Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions,” European Journal of Neuroscience, vol. 11, no. 10, pp. 3585–3596, 1999. View at Publisher · View at Google Scholar
  26. M. R. Marien, F. C. Colpaert, and A. C. Rosenquist, “Noradrenergic mechanisms in neurodegenerative diseases: a theory,” Brain Research Reviews, vol. 45, no. 1, pp. 38–78, 2004. View at Publisher · View at Google Scholar · View at PubMed
  27. K. S. Rommelfanger, G. L. Edwards, K. G. Freeman, L. C. Liles, G. W. Miller, and D. Weinshenker, “Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13804–13809, 2007. View at Publisher · View at Google Scholar · View at PubMed
  28. E. Hasegawa, K. Takeshige, T. Oishi, Y. Murai, and S. Minakami, “1-Methyl-4-phenylpyridinium (MPP) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles,” Biochemical and Biophysical Research Communications, vol. 170, no. 3, pp. 1049–1055, 1990. View at Publisher · View at Google Scholar
  29. E. Fahre, J. Monserrat, A. Herrero, G. Barja, and M. L. Leret, “Effect of MPTP on brain mitochondrial HO and ATP production and on dopamine and DOPAC in the striatum,” Journal of Physiology and Biochemistry, vol. 55, no. 4, pp. 325–332, 1999. View at Google Scholar
  30. T. P. Singer, R. R. Ramsay, K. McKeown, A. Trevor, and N. E. Castagnoli, “Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Toxicology, vol. 49, no. 1, pp. 17–23, 1988. View at Google Scholar
  31. J. M. C. Gutteridge, “Iron and oxygen radicals in brain,” Annals of Neurology, vol. 32, pp. S16–S21, 1992. View at Google Scholar
  32. Z. I. Alam, A. Jenner, S. E. Daniel et al., “Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1196–1203, 1997. View at Google Scholar
  33. J. Zhang, G. Perry, M. A. Smith et al., “Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons,” American Journal of Pathology, vol. 154, no. 5, pp. 1423–1429, 1999. View at Google Scholar
  34. E. C. Hirsch and S. Hunot, “Neuroinflammation in Parkinson's disease: a target for neuroprotection?” The Lancet Neurology, vol. 8, no. 4, pp. 382–397, 2009. View at Publisher · View at Google Scholar
  35. D. G. Graham, “Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones,” Molecular Pharmacology, vol. 14, no. 4, pp. 633–643, 1978. View at Google Scholar
  36. J. Boada, B. Cutillas, T. Roig, J. Bermúdez, and S. Ambrosio, “MPP+-induced mitochondrial dysfunction is potentiated by dopamine,” Biochemical and Biophysical Research Communications, vol. 268, no. 3, pp. 916–920, 2000. View at Publisher · View at Google Scholar · View at PubMed
  37. B. Drukarch and F. L. van Muiswinkel, “Neuroprotection for Parkinson's disease: a new approach for a new millennium,” Expert Opinion on Investigational Drugs, vol. 10, no. 10, pp. 1855–1868, 2001. View at Publisher · View at Google Scholar · View at PubMed
  38. B. S. Mandavilli, S. F. Ali, and B. Van Houten, “DNA damage in brain mitochondria caused by aging and MPTP treatment,” Brain Research, vol. 885, no. 1, pp. 45–52, 2000. View at Publisher · View at Google Scholar
  39. H. Yamaguchi, K. Kajitani, Y. Dan et al., “MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Cell Death and Differentiation, vol. 13, no. 4, pp. 551–563, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. M. L. Selley, “(E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease,” Free Radical Biology and Medicine, vol. 25, no. 2, pp. 169–174, 1998. View at Publisher · View at Google Scholar
  41. L. I. P. Liang, J. Huang, R. Fulton, B. J. Day, and M. Patel, “An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo,” Journal of Neuroscience, vol. 27, no. 16, pp. 4326–4333, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. M. S. Saporito, B. A. Thomas, and R. W. Scott, “MPTP activates c-Jun NH-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo,” Journal of Neurochemistry, vol. 75, no. 3, pp. 1200–1208, 2000. View at Publisher · View at Google Scholar
  43. S. Karunakaran, U. Saeed, M. Mishra et al., “Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice,” Journal of Neuroscience, vol. 28, no. 47, pp. 12500–12509, 2008. View at Publisher · View at Google Scholar · View at PubMed
  44. S. Karunakaran and V. Ravindranath, “Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-κB in MPTP-treated mice: implication in Parkinson's disease,” Journal of Neurochemistry, vol. 109, no. 6, pp. 1791–1799, 2009. View at Publisher · View at Google Scholar · View at PubMed
  45. M. Vila, V. Jackson-Lewis, S. Vukosavic et al., “Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2837–2842, 2001. View at Publisher · View at Google Scholar · View at PubMed
  46. H. Kamiya and H. Kasai, “Formation of 2-hydroxydeoxyadenosine triphosphate, an oxidatively damaged nucleotide, and its incorporation by DNA polymerases. Steady-state kinetics of the incorporation,” The Journal of Biological Chemistry, vol. 270, no. 33, pp. 19446–19450, 1995. View at Publisher · View at Google Scholar
  47. Y. Nakabeppu, D. Tsuchimoto, H. Yamaguchi, and K. Sakumi, “Oxidative damage in nucleic acids and Parkinson's disease,” Journal of Neuroscience Research, vol. 85, no. 5, pp. 919–934, 2007. View at Publisher · View at Google Scholar · View at PubMed
  48. M. Ohno, S. Oka, and Y. Nakabeppu, “Quantitative analysis of oxidized guanine, 8-oxoguanine, in mitochondrial DNA by immunofluorescence method,” Methods in Molecular Biology, vol. 554, pp. 199–212, 2009. View at Publisher · View at Google Scholar
  49. S. Oka, M. Ohno, D. Tsuchimoto, K. Sakumi, M. Furuichi, and Y. Nakabeppu, “Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs,” The EMBO Journal, vol. 27, no. 2, pp. 421–432, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. M. L. Michaels, J. Tchou, A. P. Grollman, and J. H. Miller, “A repair system for 8-oxo-7,8-dihydrodeoxyguanine,” Biochemistry, vol. 31, no. 45, pp. 10964–10968, 1992. View at Publisher · View at Google Scholar
  51. S. Hirano, Y. Tominaga, A. Ichinoe et al., “Mutator phenotype of MUTYH-null mouse embryonic stem cells,” The Journal of Biological Chemistry, vol. 278, no. 40, pp. 38121–38124, 2003. View at Publisher · View at Google Scholar · View at PubMed
  52. Y. Tominaga, Y. Ushijima, D. Tsuchimoto et al., “MUTYH prevents OGG1 or APEX1 from inappropriately processing its substrate or reaction product with its C-terminal domain,” Nucleic Acids Research, vol. 32, no. 10, pp. 3198–3211, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. M. L. Michaels, J. Tchou, A. P. Grollman, and J. H. Miller, “A repair system for 8-oxo-7,8-dihydrodeoxyguanine,” Biochemistry, vol. 31, no. 45, pp. 10964–10968, 1992. View at Publisher · View at Google Scholar
  54. G. Simbula, P. A. Glascott Jr., S. Akita, J. B. Hoek, and J. L. Farber, “Two mechanisms by which ATP depletion potentiates induction of the mitochondrial permeability transition,” American Journal of Physiology, vol. 273, no. 2, pp. C479–C488, 1997. View at Google Scholar
  55. P. S. Vosler, C. S. Brennan, and J. Chen, “Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration,” Molecular Neurobiology, vol. 38, no. 1, pp. 78–100, 2008. View at Publisher · View at Google Scholar · View at PubMed
  56. S. J. Crocker, P. D. Smith, V. Jackson-Lewis et al., “Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease,” Journal of Neuroscience, vol. 23, no. 10, pp. 4081–4091, 2003. View at Google Scholar
  57. T. Eki and J. Hurwitz, “Influence of poly(ADP-ribose) polymerase on the enzymatic synthesis of SV40 DNA,” The Journal of Biological Chemistry, vol. 266, no. 5, pp. 3087–3100, 1991. View at Google Scholar
  58. C. Soldani and A. I. Scovassi, “Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update,” Apoptosis, vol. 7, no. 4, pp. 321–328, 2002. View at Publisher · View at Google Scholar
  59. S. W. Yu, H. Wang, M. F. Poitras et al., “Mediation of poty(ADP-ribose) polymerase-1—dependent cell death by apoptosis-inducing factor,” Science, vol. 297, no. 5579, pp. 259–263, 2002. View at Publisher · View at Google Scholar · View at PubMed
  60. A. S. Mandir, S. Przedborski, V. Jackson-Lewis et al., “Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5774–5779, 1999. View at Google Scholar
  61. H. Wang, M. Shimoji, S. W. Yu, T. M. Dawson, and V. L. Dawson, “Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 991, pp. 132–139, 2003. View at Google Scholar
  62. S. Veto, P. Acs, J. Bauer et al., “Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death,” Brain, vol. 133, no. 3, pp. 822–834, 2010. View at Publisher · View at Google Scholar · View at PubMed
  63. C. C. Alano, W. Ying, and R. A. Swanson, “Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD depletion and mitochondrial permeability transition,” The Journal of Biological Chemistry, vol. 279, no. 18, pp. 18895–18902, 2004. View at Publisher · View at Google Scholar · View at PubMed
  64. R. Heikkila and G. Cohen, “Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine,” Science, vol. 172, no. 3989, pp. 1257–1258, 1971. View at Google Scholar
  65. G. Cohen and R. E. Heikkila, “The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6 hydroxydopamine, dialuric acid, and related cytotoxic agents,” The Journal of Biological Chemistry, vol. 249, no. 8, pp. 2447–2452, 1974. View at Google Scholar
  66. D. Blum, S. Torch, N. Lambeng et al., “Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease,” Progress in Neurobiology, vol. 65, no. 2, pp. 135–172, 2001. View at Publisher · View at Google Scholar
  67. A. Slivka and G. Cohen, “Hydroxyl radical attack on dopamine,” The Journal of Biological Chemistry, vol. 260, no. 29, pp. 15466–15472, 1985. View at Google Scholar
  68. K. Jellinger, L. Linert, E. Kienzl, E. Herlinger, and M. B. H. Youdim, “Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease,” Journal of Neural Transmission, Supplement, no. 46, pp. 297–314, 1995. View at Google Scholar
  69. W. Linert, E. Herlinger, R. F. Jameson, E. Kienzl, K. Jellinger, and M. B. H. Youdim, “Dopamine, 6-hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1316, no. 3, pp. 160–168, 1996. View at Publisher · View at Google Scholar
  70. A. Palumbo, A. Napolitano, P. Barone, and M. D'Ischia, “Nitrite- and peroxide-dependent oxidation pathways of dopamine: 6- nitrodopamine and 6-hydroxydopamine formation as potential contributory mechanisms of oxidative stress- and nitric oxide-induced neurotoxicity in neuronal degeneration,” Chemical Research in Toxicology, vol. 12, no. 12, pp. 1213–1222, 1999. View at Publisher · View at Google Scholar
  71. C. D. Garner and J. P. Nachtman, “Manganese catalyzed auto-oxidation of dopamine to 6-hydroxydopamine in vitro,” Chemico-Biological Interactions, vol. 69, no. 4, pp. 345–351, 1989. View at Google Scholar
  72. G. R. Breese and T. D. Traylor, “Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine,” British Journal of Pharmacology, vol. 42, no. 1, pp. 88–99, 1971. View at Google Scholar
  73. F. Karoum, S. J. Chrapusta, M. F. Egan, and R. J. Wyatt, “Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study,” Journal of Neurochemistry, vol. 61, no. 4, pp. 1369–1375, 1993. View at Google Scholar
  74. G. S. Kaminski Schierle, O. Hansson, E. Ferrando-May, P. Nicotera, P. Brundin, and M. Leist, “Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation,” NeuroReport, vol. 10, no. 16, pp. 3347–3351, 1999. View at Google Scholar
  75. F. L. van Muiswinkel, B. Drukarch, H. W. M. Steinbusch, and J. De Vente, “Sustained pharmacological inhibition of nitric oxide synthase does not affect the survival of intrastriatal rat fetal mesencephalic transplants,” Brain Research, vol. 792, no. 1, pp. 48–58, 1998. View at Publisher · View at Google Scholar
  76. I. Ohsawa, M. Ishikawa, K. Takahashi et al., “Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals,” Nature Medicine, vol. 13, no. 6, pp. 688–694, 2007. View at Publisher · View at Google Scholar · View at PubMed
  77. K. Nagata, N. Nakashima-Kamimura, T. Mikami, I. Ohsawa, and S. Ohta, “Consumption of molecular hydrogen prevents the stress-induced impairments in hippocampus-dependent learning tasks during chronic physical restraint in mice,” Neuropsychopharmacology, vol. 34, no. 2, pp. 501–508, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. Y. Gu, C. S. Huang, T. Inoue et al., “Drinking hydrogen water ameliorated cognitive impairment in senescence-accelerated mice,” Journal of Clinical Biochemistry and Nutrition, vol. 46, no. 3, pp. 269–276, 2010. View at Publisher · View at Google Scholar · View at PubMed
  79. K. I. Fukuda, S. Asoh, M. Ishikawa, Y. Yamamoto, I. Ohsawa, and S. Ohta, “Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress,” Biochemical and Biophysical Research Communications, vol. 361, no. 3, pp. 670–674, 2007. View at Publisher · View at Google Scholar · View at PubMed
  80. B. M. Buchholz, D. J. Kaczorowski, R. Sugimoto et al., “Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury,” American Journal of Transplantation, vol. 8, no. 10, pp. 2015–2024, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. A. Nakao, D. J. Kaczorowski, Y. Wang et al., “Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both,” Journal of Heart and Lung Transplantation, vol. 29, no. 5, pp. 544–553, 2010. View at Publisher · View at Google Scholar · View at PubMed
  82. K. Hayashida, M. Sano, I. Ohsawa et al., “Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury,” Biochemical and Biophysical Research Communications, vol. 373, no. 1, pp. 30–35, 2008. View at Publisher · View at Google Scholar · View at PubMed
  83. I. Ohsawa, K. Nishimaki, K. Yamagata, M. Ishikawa, and S. Ohta, “Consumption of hydrogen water prevents atherosclerosis in apolipoprotein E knockout mice,” Biochemical and Biophysical Research Communications, vol. 377, no. 4, pp. 1195–1198, 2008. View at Publisher · View at Google Scholar · View at PubMed
  84. Y. Fu, M. Ito, Y. Fujita et al., “Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease,” Neuroscience Letters, vol. 453, no. 2, pp. 81–85, 2009. View at Publisher · View at Google Scholar · View at PubMed
  85. E. C. Stack, J. L. Ferro, J. Kim et al., “Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1782, no. 3, pp. 151–162, 2008. View at Publisher · View at Google Scholar · View at PubMed
  86. K. I. Setsukinai, Y. Urano, K. Kakinuma, H. J. Majima, and T. Nagano, “Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species,” The Journal of Biological Chemistry, vol. 278, no. 5, pp. 3170–3175, 2003. View at Publisher · View at Google Scholar · View at PubMed
  87. Y. Sato, S. Kajiyama, A. Amano et al., “Hydrogen-rich pure water prevents superoxide formation in brain slices of vitamin C-depleted SMP30/GNL knockout mice,” Biochemical and Biophysical Research Communications, vol. 375, no. 3, pp. 346–350, 2008. View at Publisher · View at Google Scholar · View at PubMed
  88. A. Nakao, Y. Toyoda, P. Sharma, M. Evans, and N. Guthrie, “Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome—an open label pilot study,” Journal of Clinical Biochemistry and Nutrition, vol. 46, no. 2, pp. 140–149, 2010. View at Publisher · View at Google Scholar · View at PubMed
  89. J. Alam and J. L. Cook, “How many transcription factors does it take to turn on the heme oxygenase-1 gene?” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 2, pp. 166–174, 2007. View at Publisher · View at Google Scholar · View at PubMed
  90. D. T. Dexter, F. R. Wells, F. Agid et al., “Increased nigral iron content in postmortem Parkinsonian brain,” The Lancet, vol. 2, no. 8569, pp. 1219–1220, 1987. View at Google Scholar
  91. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtman, and Y. Mizuno, “Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 7, pp. 2696–2701, 1996. View at Publisher · View at Google Scholar
  92. Z. I. Alam, S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell, “A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1326–1329, 1997. View at Google Scholar
  93. H. Shimura-Miura, N. Hattori, D. Kang, K. I. Miyako, Y. Nakabeppu, and Y. Mizuno, “Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease,” Annals of Neurology, vol. 46, no. 6, pp. 920–924, 1999. View at Publisher · View at Google Scholar